This is a preview of subscription content, log in via an institution to check access.
Reference
Tepper SJ, et al. Real-world healthcare costs and resource utilization (HRU) among patients treated with erenumab in the United States: A retrospective claims database study. The International Headache Congress - International Headache Society with the European Headache Federation Joint Congress 2021 : abstr. AL050, 8 Sep 2021. Available from: URL: https://programm.conventus.de/index.php?id=ihs-ehf2021&tx_coprogramm_programm%5Bprogramm%5D=184&tx_coprogramm_programm%5Bsession%5D=40&tx_coprogramm_programm%5BcurrentPage%5D=&tx_coprogramm_programm%5Baction%5D=programm&tx_coprogramm_programm%5Bcontroller%5D=Source&cHash=53dc0659db250552a7ac4800b4e7608c
Rights and permissions
About this article
Cite this article
Migraine treatment with erenumab appears to reduce medical costs and HRU in the USA. PharmacoEcon Outcomes News 889, 17 (2021). https://doi.org/10.1007/s40274-021-08105-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08105-2